Ascendis Pharma A/S (ASND)
ASND Stock Price Chart
Explore Ascendis Pharma A/S interactive price chart. Choose custom timeframes to analyze ASND price movements and trends.
ASND Company Profile
Discover essential business fundamentals and corporate details for Ascendis Pharma A/S (ASND) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 Jan 2015
Employees
1.02K
Website
https://ascendispharma.comCEO
Jan Moller Mikkelsen
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
ASND Financial Timeline
Browse a chronological timeline of Ascendis Pharma A/S corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 10 Feb 2026
Upcoming earnings on 13 Nov 2025
EPS estimate is -$0.54.
Earnings released on 7 Aug 2025
EPS came in at -$0.93 surpassing the estimated -$1.42 by +34.51%, while revenue for the quarter reached $186.09M , missing expectations by -20.17%.
Earnings released on 1 May 2025
EPS came in at -$1.66 falling short of the estimated -$1.56 by -6.41%, while revenue for the quarter reached $110.67M , missing expectations by -27.89%.
Earnings released on 12 Feb 2025
EPS came in at -$0.68 surpassing the estimated -$1.20 by +43.33%, while revenue for the quarter reached $180.09M , beating expectations by +43.59%.
Earnings released on 14 Nov 2024
EPS came in at -$1.89 falling short of the estimated -$1.49 by -26.85%, while revenue for the quarter reached $63.43M , missing expectations by -14.45%.
Earnings released on 3 Sept 2024
EPS came in at -$2.05 falling short of the estimated -$1.54 by -33.12%, while revenue for the quarter reached $38.71M , beating expectations by +3.01%.
Earnings released on 2 May 2024
EPS came in at -$2.48 falling short of the estimated -$1.57 by -57.96%, while revenue for the quarter reached $103.02M , beating expectations by +11.54%.
Earnings released on 7 Feb 2024
EPS came in at -$1.66 surpassing the estimated -$2.15 by +22.79%, while revenue for the quarter reached $151.44M , beating expectations by +36.28%.
Earnings released on 7 Nov 2023
EPS came in at -$3.12 falling short of the estimated -$2.63 by -18.63%, while revenue for the quarter reached $50.67M , missing expectations by -8.41%.
Earnings released on 5 Sept 2023
EPS came in at -$2.35 surpassing the estimated -$2.68 by +12.31%, while revenue for the quarter reached $51.70M , beating expectations by +18.78%.
Earnings released on 27 Apr 2023
EPS came in at -$2.12 surpassing the estimated -$2.84 by +25.35%, while revenue for the quarter reached $36.52M , beating expectations by +41.63%.
Earnings released on 16 Feb 2023
EPS came in at -$3.78 falling short of the estimated -$2.50 by -51.20%, while revenue for the quarter reached $24.66M , beating expectations by +11.86%.
Earnings released on 2 Nov 2022
EPS came in at -$3.05 falling short of the estimated -$2.52 by -21.03%, while revenue for the quarter reached $14.93M , beating expectations by +9.82%.
Earnings released on 10 Aug 2022
EPS came in at -$1.54 surpassing the estimated -$2.11 by +27.01%, while revenue for the quarter reached $6.44M , beating expectations by +7.27%.
Earnings released on 11 May 2022
EPS came in at -$2.48 falling short of the estimated -$2.25 by -10.22%, while revenue for the quarter reached $7.55M , beating expectations by +43.76%.
Earnings released on 2 Mar 2022
EPS came in at -$2.14 surpassing the estimated -$2.57 by +16.73%, while revenue for the quarter reached $5.55M , beating expectations by +64.20%.
Earnings released on 10 Nov 2021
EPS came in at -$1.73 surpassing the estimated -$2.60 by +33.46%, while revenue for the quarter reached $1.29M , missing expectations by -24.14%.
Earnings released on 25 Aug 2021
EPS came in at -$3.01 falling short of the estimated -$2.75 by -9.45%, while revenue for the quarter reached $1.21M , missing expectations by -7.03%.
Earnings released on 27 May 2021
EPS came in at -$1.41 surpassing the estimated -$2.06 by +31.55%, while revenue for the quarter reached $877.43K , missing expectations by -26.55%.
Earnings released on 10 Mar 2021
EPS came in at -$3.15 falling short of the estimated -$1.84 by -71.20%, while revenue for the quarter reached $656.11K .
Earnings released on 11 Nov 2020
EPS came in at -$2.70 falling short of the estimated -$1.88 by -43.62%, while revenue for the quarter reached $3.24M , beating expectations by +13.94%.
ASND Stock Performance
Access detailed ASND performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.